No evidence of increased risk for Coronavirus Disease 2019 (COVID-19) in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy

J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e433-e434. doi: 10.1111/jdv.16552. Epub 2020 Jun 15.

Authors

A Carugno¹, F Raponi¹, A G Locatelli¹, P Vezzoli¹, D M Gambini¹, M Di Mercurio¹, E Robustelli Test², P Sena¹

Affiliations

¹ Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.
² Dermatology Clinic, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

No abstract available

Publication types

Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / immunology
Antibodies, Monoclonal, Humanized / therapeutic use*
Dermatitis, Atopic / drug therapy*
Female
Humans
Interleukin-4 Receptor alpha Subunit / immunology*
Italy / epidemiology
Male
Middle Aged
Risk Factors
Young Adult

Substances

Antibodies, Monoclonal, Humanized
Interleukin-4 Receptor alpha Subunit
dupilumab